Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Placebo-Cetp'

Placebo-Cetp published presentations and documents on DocSlides.

CETP inhibition : Where
CETP inhibition : Where
by rodriguez
are we . now. ?. Prof. John Kastelein. Academic. ...
De-risking the development programs of CETP inhibitors after the
De-risking the development programs of CETP inhibitors after the
by scarlett
torcetrapib. failure: Endothelial function & ...
Atherosclerosis 90 1991 159168 0 Elsevier Scientific Publishers Ir
Atherosclerosis 90 1991 159168 0 Elsevier Scientific Publishers Ir
by bella
159 ATHERO 04705 Different locations of choleste...
The role of cholesteryl ester transfer protein TaqIB polymorphism in y
The role of cholesteryl ester transfer protein TaqIB polymorphism in y
by sophie
Bilal Ilanbey Meral Kayikcioglu Ebru Demirel Sez...
Cholesteryl Ester Transfer
Cholesteryl Ester Transfer
by conchita-marotz
Protein Inhibitors. Learning Objectives. Benefits...
Diabetic dyslipidemia : The pro-
Diabetic dyslipidemia : The pro-
by deborah
atherogenic. role of CETP and future use of CETP ...
Placebo (n = 38) Metoprolol
Placebo (n = 38) Metoprolol
by unita
(. n . = 37). Metoprolol for AR. Primary endpoint,...
Fludrocortisone does not reduce the risk of recurrent syncope at 12 months compared with placebo i
Fludrocortisone does not reduce the risk of recurrent syncope at 12 months compared with placebo i
by delcy
syncope. Given the trend towards benefit though, i...
Placebo (n = 2,333) Empaglifozin
Placebo (n = 2,333) Empaglifozin
by SugarPlumFairy
(. n . = 4,687). EMPA-REG OUTCOME. Primary . outco...
Alpha Omega MACE: 14.0% with EPA-DHA vs. 13.8% with placebo (p = 0.93)
Alpha Omega MACE: 14.0% with EPA-DHA vs. 13.8% with placebo (p = 0.93)
by delcy
MACE: 13.2% with ALA vs. 14.5% with placebo (p = 0...
Neratinib / Placebo treatment
Neratinib / Placebo treatment
by heartersh
0. 3. 6. 9. 12. 15. 18. 21. 24. Disease-free survi...
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular
by mitsue-stanley
ASCEND Randomized placebo-controlled trial of as...
Causal diagrams, the placebo effect, and the expectation effect
Causal diagrams, the placebo effect, and the expectation effect
by ellena-manuel
Eyal Shahar, MD, MPH. Professor. (. c. redit to D...
Anxiolytic Placebo Response in Outbred Mice
Anxiolytic Placebo Response in Outbred Mice
by natalia-silvester
Kelsey I. . Landaverde. , Stacey L. . Kirkpatrick...
What Accounts for Placebo Group
What Accounts for Placebo Group
by alida-meadow
Improvements and Can They Be Reduced?. John T. Fa...
Does Meditation Really Work or It’s Placebo effect
Does Meditation Really Work or It’s Placebo effect
by ellena-manuel
Simge ALTINKÖK. Outline. Definition of meditati...
The Placebo Effect
The Placebo Effect
by danika-pritchard
. ...
The Placebo Effect
The Placebo Effect
by alexa-scheidler
Homeopathy. In the late 1700’s a German doctor ...
The Placebo Drift Debate in Antidepressant Clinical Trials
The Placebo Drift Debate in Antidepressant Clinical Trials
by celsa-spraggs
Zach Daniel White. Biology 101h- . Desaix. Why do...
About OMICS Group OMICS Group is an amalgamation of
About OMICS Group OMICS Group is an amalgamation of
by beatrice
Open Access Publications. and worldwide internati...
Lyn Turkstra, PhD, Reg-CASLPO
Lyn Turkstra, PhD, Reg-CASLPO
by patricia
Assistant Dean, Speech-Language Pathology Program....
Residual risk and HDL-cholesterol:
Residual risk and HDL-cholesterol:
by bitsy
What are the current perspectives?. Prof. . Erik ....
LIPOPROTEIN METABOLISM Problem
LIPOPROTEIN METABOLISM Problem
by lucinda
What are lipids?. If so, how are these water insol...
Is lower better? LDL targets and beyond.
Is lower better? LDL targets and beyond.
by olivia-moreira
Implications of the relationship between risk fac...
Is lower better? LDL targets and beyond.
Is lower better? LDL targets and beyond.
by trish-goza
Implications of the relationship between risk fac...
Figure 1 Figure 1. Estimated and observed viral load following treatment with placebo (A) or Paxlov
Figure 1 Figure 1. Estimated and observed viral load following treatment with placebo (A) or Paxlov
by gian
Bai Y, Du Z, Wang L, Lau E, Fung I, Holme P, et al...
TDF-FTC versus Placebo as HIV PrEP for Transgender Women
TDF-FTC versus Placebo as HIV PrEP for Transgender Women
by shmuel184
iPrEx. Trial . Substudy. TDF-FTC versus Placebo a...
Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i
Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i
by zen
knowledge. ). Incorporate evidence-based research ...
Efficacy of Cariprazine on Cognitive Symptom Domains in Patients with Schizophrenia and Bipolar Dep
Efficacy of Cariprazine on Cognitive Symptom Domains in Patients with Schizophrenia and Bipolar Dep
by kolson
R. Csehi, . Zs. . B. Dombi. , . Á. Barabássy, B....
HIV Prevention England Conference
HIV Prevention England Conference
by felicity
18 February 2020. -. A two-stage randomised phase ...
Supplementing randomized clinical trials with historical data via Bayesian dynamic borrowing:
Supplementing randomized clinical trials with historical data via Bayesian dynamic borrowing:
by genevieve
A framework to engage with regulatory authorities....
Results from a Phase 2 Randomized, Placebo-Controlled, Double Blind Study of the
Results from a Phase 2 Randomized, Placebo-Controlled, Double Blind Study of the
by ella
Hedgehog Pathway Antagonist IPI-926 . in Patients ...
Rifaat Safadi 1 , John Lawler
Rifaat Safadi 1 , John Lawler
by ava
2. , Revital Aricha. 2. , Ilan Vaknin. 2. , Scott ...
Impact of Rosuvastatin on Atherosclerotic Progression in People with HIV at Moderate Cardiovascular
Impact of Rosuvastatin on Atherosclerotic Progression in People with HIV at Moderate Cardiovascular
by vivian
Janine Trevillyan. , Matthias . Cavassini. , Jan F...
Beyond A1c: Exploring the Expanding Role of Anti-Diabetic Agents
Beyond A1c: Exploring the Expanding Role of Anti-Diabetic Agents
by deena
Saidee Oberlander, PharmD, BCPS. Acute Care Pharma...
Safety and Antiviral Activity Over
Safety and Antiviral Activity Over
by bety
10 Days Following a Single Dose of Subcutaneous GS...
Thalidomide: Thalidomide is a medical drug that caused 
Thalidomide: Thalidomide is a medical drug that caused 
by skylar
unexpected and serious damage.  to unborn babies ...
Mark Whitlock Head of Statistics for Internal Medicine RU
Mark Whitlock Head of Statistics for Internal Medicine RU
by bethany
Early Clinical Devel. opment. Pfizer. Is High Plac...
DR.RAMYA S.S ASSISTANT PROFESSOR
DR.RAMYA S.S ASSISTANT PROFESSOR
by tremblay
DEPT OF HOMOEOPATHIC PHARMACY. PLACEBO. PLACEBO ...
Evidence Based Medicine In
Evidence Based Medicine In
by megan
Pharmacy Practice. Jarrod King, Pharm. D. . PGY1 U...